Drug Trial Radar · NCT06942936
A Study to Investigate the Impact of Multiple Doses of Itraconazole on AZD5004 in Healthy Participants and Multiple Doses of AZD5004 on Combined Oral Ethinyl Oestradiol and Levonorgestrel in Healthy Female Participants
Last checked: Nov 19, 2026Latest source record: Feb 3, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
51
Actual
Start
May 28, 2025
Primary completion
Jan 28, 2026
Study completion Jan 28, 2026
Sponsor
- Lead sponsor
- AstraZenecaAstraZeneca (AZN)
- Sponsor type
- Industry
- Collaborators
- Parexel
- First posted
- Apr 24, 2025
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Non randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 70 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
The purpose of this study is to assess the impact of multiple doses of itraconazole on the pharmacokinetics (PK) of AZD5004 in healthy participants (Part A), and to assess the impact of multiple doses of AZD5004 on the PK of Combined Oral Contraceptives (COCs) in healthy female participants (Part B).
Conditions
- Healthy Participants
Interventions
AZD5004Drug
AZD50004 is administered orally as a tablet.
ItraconazoleDrug
Itraconazole is administered orally as a capsule.
EE/LNGDrug
EE/LNG is administered orally in the form of tablet.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Part A: Area under concentration-time curve from time zero to infinity (AUCinf) of AZD5004Time frame: Day 1 and Day 10
- Part A: Area under concentration-curve from time 0 to the last quantifiable concentration (AUClast) of AZD5004Time frame: Day 1 and Day 10
- Part A: Maximum observed drug concentration (Cmax) of AZD5004Time frame: Day 1 and Day 10
- Part A: Terminal elimination half-life (t1/2λz) of AZD5004Time frame: Day 1 and Day 10
- Part A: Time to reach maximum observed concentration (tmax) of AZD5004Time frame: Day 1 and Day 10
- Part A: Apparent total body clearance (CL/F) of AZD5004Time frame: Day 1 and Day 10
- Part A: Apparent volume of distribution based on the terminal phase (Vz) of AZD5004Time frame: Day 1 and Day 10
- Part B: Area under concentration-time curve from time zero to infinity (AUCinf) of EE/LNGTime frame: Day 1, Day 8, Day 50 and Day 78
- Part B: Area under concentration-curve from time 0 to the last quantifiable concentration (AUClast) of EE/LNGTime frame: Day 1, Day 8, Day 50 and Day 78
- Part B: Maximum observed drug concentration (Cmax) of EE/LNGTime frame: Day 1, Day 8, Day 50 and Day 78
- Part B: Terminal elimination half-life (t1/2λz) of EE/LNGTime frame: Day 1, Day 8, Day 50 and Day 78
- Part B: Time to reach maximum observed concentration (tmax) of EE/LNGTime frame: Day 1, Day 8, Day 50 and Day 78
- Part B: Apparent total body clearance (CL/F) of EE/LNGTime frame: Day 1, Day 8, Day 50 and Day 78
- Part B: Apparent volume of distribution based on the terminal phase (Vz) of EE/LNGTime frame: Day 1, Day 8, Day 50 and Day 78
Locations
2 sites in 2 countries. Site status is shown where the registry gives one.
Research Site
Baltimore, Maryland
Research Site
Berlin, Germany
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.